Data Readout

Veru sets Q1 2027 interim look at enobosarm's bid to beat GLP-1 weight-loss plateau

The Phase 2b PLATEAU trial will test whether enobosarm preserves lean mass and extends weight loss beyond semaglutide alone, building on a positive earlier study in the same combination.

By AppliedXLJuly 13, 2026Trial NCT07446998

Executive Summary

Veru's Phase 2b PLATEAU trial is testing whether an oral androgen receptor drug can preserve muscle during GLP-1 weight loss, with an early look at that mechanism due before the trial's real endpoint reads out.
The approach targets a problem GLP-1 drugs don't solve, muscle and function loss during rapid weight reduction, rather than competing on total weight lost.
Veru's own earlier study in the same combination found preserved lean mass and greater fat loss, giving this trial a same-drug precedent to build on rather than a first attempt.
The Q1 2027 data will speak to body composition, not to the total-body-weight result the trial is designed to prove, so it functions as a signpost rather than a verdict.

The trial

PLATEAU (NCT07446998) is a double-blind, placebo-controlled Phase 2 study enrolling approximately 200 patients aged 65 and older with obesity (BMI at least 35) who are starting semaglutide treatment. The primary endpoint is percent change from baseline in total body weight at 68 weeks, comparing enobosarm plus semaglutide against semaglutide alone. An interim analysis at 36 weeks will assess percent change from baseline in lean body mass and fat mass by DXA scan, with data expected in the first quarter of 2027. The trial started recruiting on March 26, 2026, and its primary completion date is registered as October 1, 2027. NCT07446998+1

Probability of Success

Endpoint Met77%

Completes95%

Clinical Significance21%

Regulatory52%

The mechanism and the problem it targets

Enobosarm is an oral selective androgen receptor modulator that Veru is developing to make GLP-1-driven weight loss more selective for fat rather than lean tissue, aiming for what the company calls higher quality weight reduction that preserves muscle and physical function. Semaglutide and other GLP-1 receptor agonists drive total weight loss but do not distinguish fat loss from muscle loss, a gap PLATEAU is designed to probe rather than the total-weight-loss race itself. Veru

Prior evidence

Veru's completed Phase 2 QUALITY study (NCT06282458), which enrolled 168 patients, reported that enobosarm plus semaglutide preserved lean mass and physical function and produced greater fat loss during a 16-week active weight-loss period, with total weight loss similar across arms at 16 weeks. PLATEAU extends that same combination into an older population over a longer horizon, using semaglutide again as the GLP-1 backbone, a choice Veru has said may also inform a future oral-enobosarm-plus-oral-semaglutide combination since no oral tirzepatide formulation exists. Veru

Where enobosarm sits competitively

No other industry trial pairs an androgen receptor modulator with a GLP-1 agonist for obesity; the androgen receptor programs active in clinical testing sit almost entirely in prostate cancer, hypogonadism, and androgenetic alopecia, with sponsors including Bayer, Novartis, and Jiangsu HengRui Medicine developing androgen receptor drugs for those indications rather than for weight management. Given that isolation, the informative outcome for PLATEAU is not whether it out-loses the dominant GLP-1 field on total weight, but whether the lean-mass preservation signal from the QUALITY study replicates at 36 weeks in an older, higher-BMI population and holds through the 68-week primary analysis.

Operational read

The trial's enrollment target has not changed since its first registry posting, sitting flat at 200 patients, which the operational model reads as within the routine range rather than a warning sign. Its only tracked protocol edit is a single eligibility-criteria modification, and the registry shows no primary-completion-date changes to date. Veru has issued the same Q1 2027 guidance window twice, in press releases dated May 6 and May 13, 2026, without shifting the date. NCT07446998+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.